Intracranial Arteriosclerosis: Clinical Trials

2 trials for Intracranial Arteriosclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Terminated 2

Follow Intracranial Arteriosclerosis: new trials by email Literature Review of Intracranial Arteriosclerosis trials Research Report on Intracranial Arteriosclerosis

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
CY6463, Placebo - Alzheimer's Disease With Vascular Pathology
Phase 2TerminatedTisento Therapeutics122021-11-022024-10-30
Vitamin E and C to Slow Progression of Common Carotid Artery Plaque Build-Up
Vitamin E, Vitamin C - Cardiovascular Diseases, Carotid Artery Diseases
Phase 2TerminatedNational Heart, Lung, and Blood Institute (NHLBI)1995-06-012013-12-13

Narrower conditions

Alzheimer Disease (1)  ·  Atherosclerosis (1)  ·  Cardiovascular Diseases (1)  ·  Carotid Artery Diseases (1)  ·  Cerebrovascular Disorders (1)  ·  Dementia, Vascular (1)  ·  Heart Diseases (1)  ·  Mixed Dementias (1)  ·  Vascular Diseases (1)

Broader conditions

Arterial Occlusive Diseases (2)  ·  Arteriosclerosis (2)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Intracranial Arterial Diseases (2)  ·  Nervous System Diseases (2)  ·  Cardiovascular Diseases (1)  ·  Cerebrovascular Disorders (1)  ·  Dementia (1)  ·  Leukoencephalopathies (1)  ·  Mental Disorders (1)  ·  Neurocognitive Disorders (1)  ·  Neurodegenerative Diseases (1)  ·  Tauopathies (1)

Interventions

Ascorbic Acid (1)  ·  Vitamin E (1)

Sponsors

National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  Tisento Therapeutics (1)

Countries

United States (1)

Top investigators

James H. Dwyer, III (1)

NIH funding

U01HL052073 (1)